About: Isolated olfactory cleft involvement in SARS-CoV-2 infection: prevalence and clinical correlates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Isolated olfactory cleft involvement in SARS-CoV-2 infection: prevalence and clinical correlates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Isolated olfactory cleft involvement in SARS-CoV-2 infection: prevalence and clinical correlates
Creator	Felisati, Giovanni Cariati, Maurizio Pipolo, Carlotta Castellani, · De Donato, Giuseppe Lozza, Paolo Maccari, Alberto Pisani, Antonia Portaleone, Sara Saibene, Alberto Scotti, Alberto Spoldi, Chiara
Source	Medline; PMC
abstract	PURPOSE: Smell alterations are a symptom of COVID-19 and have been associated with olfactory cleft mucosal thickening (OCMT). Although their pathogenesis is unclear, evidences link them to viral neuroinvasive potential. This study aims at estimating the prevalence of OCMT in CT scans of COVID-19 patients and investigating its clinical correlates. METHODS: In a single-institution retrospective cross-sectional study, we included all patients hospitalized for COVID-19 undergoing head CT scan for any reason. Exclusion criteria were history of recent head trauma or chronic rhinosinusitis; opacification > 2 mm in any sinonasal space other than the olfactory cleft; CT performed during/after invasive ventilation or feeding via nasogastric tube. We recorded the prevalence of OCMT and related it to age, sex, need for invasive ventilation during hospital stay, outcome, length of hospital stay, diffusion of lung SARS-CoV-19 lesions and outcome. RESULTS: 63 eligible patients were identified (39 male, 24 female; median age 77.82 ± 17.77 years). OCMT was identified in 16 patients (25.4%; 95% CI 15.3–37.9%). Patients with OCMT had longer hospital stays (median 16 ± 4 vs. 9 ± 14.5 days, p = .009, Mann–Whitney U test) and required invasive ventilation more frequently than patients without mucosal thickening (OR 4.89, 95% CI 0.96–24.89, p = .063, Fisher’s test). No other difference was observed. CONCLUSION: OCMT affects nearly one in four patients hospitalized for COVID-19. It is associated with a worse disease course irrespective of age, sex and diffusion of lung lesions, although with no direct effect on survival.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1007/s00405-020-06165-7
bibo:pmid	32577901
has license	no-cc
sha1sum (hex)	4a4eed007271d1cbb08fcfb29a81bdda2885f5c7
schema:url	https://doi.org/10.1007/s00405-020-06165-7
resource representing a document's title	Isolated olfactory cleft involvement in SARS-CoV-2 infection: prevalence and clinical correlates
has PubMed Central identifier	PMC7309200
has PubMed identifier	32577901
schema:publication	Eur Arch Otorhinolaryngol
resource representing a document's body	covid:4a4eed007271d1cbb08fcfb29a81bdda2885f5c7#body_text
is schema:about of	named entity 'This' named entity 'symptom' named entity 'test' named entity 'Results' named entity 'prevalence' named entity 'ALTERATIONS' named entity 'DIFFUSION' named entity 'UNCLEAR' named entity 'OPACIFICATION' named entity 'TEST' named entity 'FEEDING' named entity 'OLFACTORY' named entity 'DAYS' named entity 'CT scan' named entity 'stay' named entity 'frequently' named entity 'investigating' named entity 'mucosal' named entity 'age' named entity 'viral' named entity 'retrospective' named entity 'stays' named entity 'patients' named entity 'SARS-CoV' named entity 'cross-sectional study' named entity 'symptom' named entity 'CT scan' named entity '95% CI' named entity 'Oto-Rhino-Laryngology' named entity 'length of hospital stay' named entity 'infection' named entity 'case report' named entity 'Fisher test' named entity 'olfactory' named entity 'olfactory' named entity 'central nervous' named entity '3, 4' named entity 'radiological studies' named entity 'central nervous' named entity 'neurological symptoms' named entity 'Informed consent' named entity 'first-line' named entity 'tertiary care' named entity 'statistical analyses' named entity 'retrospective study' named entity 'radiological studies' named entity 'Armonk' named entity 'clinical significance' named entity 'COVID' named entity 'teaching hospital' named entity 'invasive ventilation' named entity 'olfactory' named entity 'central nervous' named entity 'pathophysiological' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'olfactory' named entity 'olfactory mucosa' named entity 'SARS' named entity 'ethical standards' named entity 'ectomesenchymal' named entity 'CT scan' named entity 'nasogastric tube' named entity 'mucosal' named entity 'clinical indication' named entity 'CT scan' named entity 'CT scans' named entity 'ethical standards' named entity 'lung' named entity 'neuroinvasive'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software